The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition
- PMID: 24378347
- DOI: 10.3892/ijo.2013.2240
The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition
Abstract
Breast cancer is one of the most common malignancies in women. Approximately 15% of the patients belong to the triple-negative breast cancer (TNBC) group, and have the disadvantage of not benefiting from currently available receptor-targeted systemic therapies. Some cancers in the TNBC group harbor defects in DNA double-strand break repair by homologous recombination (HR), such as BRCA1 dysfunction, and are hypersensitive to poly (ADP-ribose) polymerase (PARP) inhibition. However, only a small fraction of the tumors are BRCA-deficient, and this restricts the therapeutic utility of the PARP inhibitor monotherapy. Cyclin-dependent kinase 1 (CDK1) is necessary not only for BRCA1-mediated S phase checkpoint activation, but also for HR, because it phosphorylates BRCA1 for the efficient formation of BRCA1 foci. In this study, we showed that the combined inhibition of CDK1 and PARP in BRCA-proficient MDA-MB-231 breast cancer cells resulted in dramatically reduced cell growth compared to PARP inhibition alone. Mechanistic investigations revealed that this sensitivity appears to be mediated by sustained DNA damage and inefficient DNA repair triggering mitochondrial-mediated apoptosis as well as autophagy. Our results suggest that CDK1 inhibition represents a plausible strategy for expanding the utility of PARP inhibitors to BRCA‑proficient breast cancers.
Similar articles
-
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.Cell Rep. 2016 Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077. Cell Rep. 2016. PMID: 27880910 Free PMC article.
-
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.Nat Med. 2011 Jun 26;17(7):875-82. doi: 10.1038/nm.2377. Nat Med. 2011. PMID: 21706030 Free PMC article.
-
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.Clin Cancer Res. 2016 Apr 1;22(7):1699-712. doi: 10.1158/1078-0432.CCR-15-1772. Epub 2015 Nov 6. Clin Cancer Res. 2016. PMID: 26546619 Free PMC article.
-
BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.Adv Exp Med Biol. 2017;1026:271-286. doi: 10.1007/978-981-10-6020-5_13. Adv Exp Med Biol. 2017. PMID: 29282689 Review.
-
Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.J Cell Physiol. 2023 Aug;238(8):1625-1640. doi: 10.1002/jcp.31015. Epub 2023 Apr 12. J Cell Physiol. 2023. PMID: 37042191 Review.
Cited by
-
Proteomic Analysis Revealed the Potential Role of MAGE-D2 in the Therapeutic Targeting of Triple-Negative Breast Cancer.Mol Cell Proteomics. 2024 Jan;23(1):100703. doi: 10.1016/j.mcpro.2023.100703. Epub 2023 Dec 20. Mol Cell Proteomics. 2024. PMID: 38128647 Free PMC article.
-
The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities.Cancer Drug Resist. 2023 Jul 28;6(3):499-516. doi: 10.20517/cdr.2023.08. eCollection 2023. Cancer Drug Resist. 2023. PMID: 37842243 Free PMC article. Review.
-
In Silico Mixed Ligand/Structure-Based Design of New CDK-1/PARP-1 Dual Inhibitors as Anti-Breast Cancer Agents.Int J Mol Sci. 2023 Sep 6;24(18):13769. doi: 10.3390/ijms241813769. Int J Mol Sci. 2023. PMID: 37762072 Free PMC article.
-
Hydroquinidine displays a significant anticarcinogenic activity in breast and ovarian cancer cells via inhibiting cell-cycle and stimulating apoptosis.Turk J Biol. 2023 Jan 11;47(1):44-60. doi: 10.55730/1300-0152.2640. eCollection 2023. Turk J Biol. 2023. PMID: 37529110 Free PMC article.
-
Targeting CDK1 in cancer: mechanisms and implications.NPJ Precis Oncol. 2023 Jun 13;7(1):58. doi: 10.1038/s41698-023-00407-7. NPJ Precis Oncol. 2023. PMID: 37311884 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous